Company to present updated data from the Phase 3 ENLIGHTED trial of Padeliporn VTP in LG UTUC with topline data expected in 2026 – Additional preliminary data from the Phase 1 trial in LA-PDAC to be presented at ASCO; initial data from rst cohort show promising signs of efcacy with a well-tolerated safety prole – … Continued

Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – LA-PDAC program represents large market opportunity in highest unmet need patients, with potential for accelerated registrational pathway; additional results from Phase 1 trial expected in 2026 – Topline data … Continued

Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) Initial durability data shows all patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date Padeliporfin … Continued

TEL AVIV, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade … Continued

Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP –   TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stagebiotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that the first … Continued